The firm brings unique experience to tracking, assessing and explaining regulatory and reimbursement policy that affect the biopharmaceutical industry. The company’s goal is to advance mutual understanding among policymakers, business executives and the investment community, in the belief that a deeper understanding of policy leads to better business, and a deeper understanding of business leads to better policy.
Member Sign In:
- Antibiotic Resistance Presidential Council Asked To Weigh In On Incentives For Rx Developers, Updates On National Plan Oct. 02, 2015
- FDA Advisory Committee Tracker: Long-Shots Will Test Pro-Approval Climate In Final Months of 2015 Sep. 30, 2015
- Advisory Committee Trends: Panels Voting “Yes” 88% of the Time; NMEs Have Perfect Record So Far In 2015 Sep. 30, 2015
See More Research Notes